BeyondSpring (BYSI) Competitors $1.69 -0.06 (-3.43%) (As of 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BYSI vs. FULC, ACB, LXEO, FATE, DMAC, TNYA, ATAI, ZNTL, ACRV, and ACRSShould you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), DiaMedica Therapeutics (DMAC), Tenaya Therapeutics (TNYA), Atai Life Sciences (ATAI), Zentalis Pharmaceuticals (ZNTL), Acrivon Therapeutics (ACRV), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. BeyondSpring vs. Fulcrum Therapeutics Aurora Cannabis Lexeo Therapeutics Fate Therapeutics DiaMedica Therapeutics Tenaya Therapeutics Atai Life Sciences Zentalis Pharmaceuticals Acrivon Therapeutics Aclaris Therapeutics BeyondSpring (NASDAQ:BYSI) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Do analysts recommend BYSI or FULC? Fulcrum Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 105.13%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has stronger earnings and valuation, BYSI or FULC? BeyondSpring has higher earnings, but lower revenue than Fulcrum Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeyondSpring$1.88M35.16-$21.03MN/AN/AFulcrum Therapeutics$80.87M3.03-$97.33M-$0.31-14.68 Does the media refer more to BYSI or FULC? In the previous week, Fulcrum Therapeutics had 4 more articles in the media than BeyondSpring. MarketBeat recorded 4 mentions for Fulcrum Therapeutics and 0 mentions for BeyondSpring. Fulcrum Therapeutics' average media sentiment score of 0.44 beat BeyondSpring's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment BeyondSpring Neutral Fulcrum Therapeutics Neutral Is BYSI or FULC more profitable? BeyondSpring's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BeyondSpringN/A N/A N/A Fulcrum Therapeutics N/A -7.31%-6.74% Does the MarketBeat Community believe in BYSI or FULC? BeyondSpring received 87 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 66.79% of users gave BeyondSpring an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformBeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% Fulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% Which has more risk & volatility, BYSI or FULC? BeyondSpring has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Do institutionals and insiders hold more shares of BYSI or FULC? 40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryFulcrum Therapeutics beats BeyondSpring on 8 of the 15 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get BeyondSpring News Delivered to You Automatically Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BYSI vs. The Competition Export to ExcelMetricBeyondSpringPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.96M$6.71B$5.22B$9.27BDividend YieldN/A3.00%5.12%4.29%P/E RatioN/A10.5887.4217.27Price / Sales35.16195.781,166.39119.60Price / CashN/A57.1543.2337.83Price / Book-1.865.164.834.93Net Income-$21.03M$151.58M$120.46M$225.34M7 Day Performance5.62%-0.64%-0.26%1.13%1 Month Performance-2.87%-3.02%15.99%2.76%1 Year Performance89.50%8.81%30.22%16.90% BeyondSpring Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BYSIBeyondSpringN/A$1.69-3.4%N/A+96.2%$65.96M$1.88M0.0080FULCFulcrum Therapeutics1.7338 of 5 stars$4.41+11.4%$9.33+111.6%-25.5%$237.87M$80.87M-13.68100News CoverageACBAurora Cannabis0.0974 of 5 stars$4.28-0.7%N/A-11.1%$234.72M$200.35M-5.671,073LXEOLexeo Therapeutics2.8366 of 5 stars$7.07+2.8%$23.80+236.6%-60.1%$233.78M$650,000.00-2.1858FATEFate Therapeutics3.58 of 5 stars$2.03+10.7%$6.75+233.3%-51.5%$230.64M$13.45M-1.22550DMACDiaMedica Therapeutics1.7926 of 5 stars$5.33-0.9%$7.00+31.3%+88.8%$227.91MN/A-9.6120Positive NewsTNYATenaya Therapeutics3.9414 of 5 stars$2.86+4.0%$17.33+506.1%-47.4%$226.57MN/A-1.91110Gap DownATAIAtai Life Sciences1.9441 of 5 stars$1.33-2.6%$9.00+579.2%-14.3%$222.34M$331,000.00-1.6883Positive NewsZNTLZentalis Pharmaceuticals2.8243 of 5 stars$3.12+1.0%$10.00+220.5%-77.9%$222.33MN/A-1.24160ACRVAcrivon Therapeutics0.9886 of 5 stars$7.04-0.3%$23.67+236.2%+27.5%$219.20MN/A-2.6158ACRSAclaris Therapeutics3.8013 of 5 stars$3.03-5.9%$8.80+190.4%+170.1%$216.44M$27.08M-5.8386Analyst UpgradeNews CoveragePositive News Related Companies and Tools Related Companies FULC Competitors ACB Competitors LXEO Competitors FATE Competitors DMAC Competitors TNYA Competitors ATAI Competitors ZNTL Competitors ACRV Competitors ACRS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BYSI) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
